pills-drugs
Makistock / shutterstock.com
26 August 2016Americas

Biosimilar cost savings yet to materialise, says healthcare organisation

Although the biosimilar market in the US is still early in development, US payers believe that the expected cost savings offer ed by biosimilar products have yet to materialise.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
25 October 2017   Introducing more biosimilars could cut healthcare spending by $54 billion over the next ten years, a figure far higher than initially thought, a think tank and research organisation has claimed.

More on this story

Americas
25 October 2017   Introducing more biosimilars could cut healthcare spending by $54 billion over the next ten years, a figure far higher than initially thought, a think tank and research organisation has claimed.

More on this story

Americas
25 October 2017   Introducing more biosimilars could cut healthcare spending by $54 billion over the next ten years, a figure far higher than initially thought, a think tank and research organisation has claimed.